Japan Radiation Oncology Market Size & Outlook, 2026-2033
The radiation oncology market in Japan is expected to reach a projected revenue of US$ 1,505.6 million by 2033. A compound annual growth rate of 9.7% is expected of Japan radiation oncology market from 2026 to 2033.
Siemens Healthineers AG ADR, Elekta AB ADR, BD, Accuray Inc, IBA RadioPharma Solutions, IsoRay, MeVis Medical Solutions AG, Nordion, Ntp Radioisotopes, Curium Pharma, ViewRay
Other key industry trends
In terms of revenue, Japan accounted for 5.1% of the global radiation oncology market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China radiation oncology market is projected to lead the regional market in terms of revenue in 2033.
India is the fastest growing regional market in Asia Pacific and is projected to reach USD 907.2 million by 2033.
Cancer is the most common cause of death in Japan. Its aging population is one of the major factors responsible for increase in prevalence of cancer. Lung cancer is the leading cause of cancer-related deaths in Japan, followed by stomach and colorectal cancers.
According to WHO, in 2018, Japan had an age-standardized cancer rate of 248.0 per 100,000 people. Moreover, a total of 883,395 new cases of cancer were recorded in Japan. Each year, approximately 13,000 patients undergo radiation therapy in Japan.
The Japanese Foundation for Cancer Research conducts radiation therapy to treat 1,700 patients per year. Geographic expansion of key players to increase their market share and introduction of novel technologies in the country are expected to boost market growth.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Radiation Oncology Market Outlook will help companies and investors design strategic landscapes.
External Beam Radiation Therapy (Ebrt) was the largest segment with a revenue share of 78.43% in 2025.
Horizon Databook has segmented the Japan radiation oncology market based on external beam radiation therapy (ebrt), internal beam radiation therapy, systemic targeted radiation therapy covering the revenue growth of each sub-segment from 2021 to 2033.
Cancer is the most common cause of death in Japan. Its aging population is one of the major factors responsible for increase in prevalence of cancer. Lung cancer is the leading cause of cancer-related deaths in Japan, followed by stomach and colorectal cancers.
According to WHO, in 2018, Japan had an age-standardized cancer rate of 248.0 per 100,000 people. Moreover, a total of 883,395 new cases of cancer were recorded in Japan. Each year, approximately 13,000 patients undergo radiation therapy in Japan.
The Japanese Foundation for Cancer Research conducts radiation therapy to treat 1,700 patients per year. Geographic expansion of key players to increase their market share and introduction of novel technologies in the country are expected to boost market growth.
Japan Radiation Oncology Market Treatment Type Outlook (Revenue, USD Million , 2021-2033)
External Beam Radiation Therapy (EBRT)
Internal Beam Radiation Therapy
Systemic Targeted Radiation Therapy
Japan Radiation Oncology Market Technology Outlook (Revenue, USD Million , 2021-2033)
Image-Guided Radiotherapy (IGRT)
Intensity-Modulated Radiotherapy (IMRT)
Volumetric Modulated Arc Therapy (VMAT)
3D Conformal Radiation Therapy (3D-CRT)
Stereotactic Radiotherapy (SRS / SBRT)
Proton Beam Delivery Technology
Heavy-Ion Delivery Technology
Adaptive Radiotherapy
Upright Beam Delivery Technology
Japan Radiation Oncology Market Application Outlook (Revenue, USD Million , 2021-2033)
External Beam Radiation Therapy (EBRT)
Internal Beam Radiation Therapy
Radioligand Therapy Applications
Japan Radiation Oncology Market Target Customer Outlook (Revenue, USD Million , 2021-2033)
Academic & Research Cancer Centers
Government & Public Tertiary Hospitals
Private Oncology Chains
Specialty Proton / Particle Therapy Centers
Nuclear Medicine & Theranostics Centers
Reasons to subscribe to Radiation Oncology Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Radiation Oncology Market Outlook databook
Our clientele includes a mix of Radiation Oncology Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Radiation Oncology Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Radiation Oncology Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.